NPS Pharma (NPSP) Submits Application to Market Teduglutide in Europe; Receives Milestone Payment
Tweet
Share
E-mailGet Alerts NPSP Hot Sheet
Join SI Premium – FREE
NPS Pharma (Nasdaq: NPSP) submits application to market teduglutide for short bowel syndrome in Europe. The submission has triggered a mid-seven digit milestone payment.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
- Alzamend Neuro (ALZN) files for 98.4M share offering by selling stockholders
- Hinge Health signs $86M office lease in San Francisco
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
